托法替布与巴瑞替尼治疗类风湿关节炎的真实世界疗效与安全性比较
该研究在真实临床实践中比较了托法替布(TOFA,n=156)与巴瑞替尼(BARI,n=138)治疗类风湿关节炎(RA)的疗效,采用倾向性评分逆概率治疗加权(IPTW)减少选择偏倚。结果显示BARI组第24周CDAI缓解率显著高于TOFA组,安全性特征相似;治疗抵抗组更多见于既往使用多种bDMARDs者及接受TOFA者。
要点
- BARI组第24周CDAI缓解率显著高于TOFA组。
- 两组安全性特征相似。
- 既往bDMARDs使用多者及TOFA组更易归入治疗抵抗组。
核心结论
- 在真实临床实践中,经IPTW最小化选择偏倚后,BARI较TOFA显示相似安全性及更优临床结局,但样本量小,需确切把握度的头对头试验进一步验证。
研究设计与样本
- 真实临床实践比较研究,TOFA组n=156,BARI组n=138,采用倾向性评分逆概率治疗加权(IPTW)减少选择偏倚,并用生长混合模型(GMM)分析CDAI轨迹。
主要发现
- 经IPTW调整后两组患者特征无显著差异。
- BARI组引入JAK抑制剂后第24周CDAI缓解率显著高于TOFA组。
- GMM定义的治疗抵抗组(第24周未达低疾病活动度)更可能包含引入JAK抑制剂前已使用多种bDMARDs者及接受TOFA者。
- 接受TOFA且引入前使用≥4种bDMARDs者更易归入治疗抵抗组。
关键数值与推荐
- 主要结局为第24周CDAI缓解率。
- 治疗抵抗定义为第24周未达低疾病活动度。
临床怎么用
- 在真实临床实践中,BARI可能较TOFA带来更高的第24周CDAI缓解率,且安全性相似。
- 对既往bDMARDs使用较多者,尤其使用≥4种后选用TOFA,治疗抵抗风险可能更高。
局限性
- 研究人群较小,需确切把握度的头对头试验进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The differences of efficacy between each Janus kinase (JAK) inhibitors have not been clarified in the patients with rheumatoid arthritis (RA) in clinical practice. Here, we compared the efficacy between tofacitinib (TOFA) and baricitinib (BARI) in clinical practice. METHODS: The efficacy of TOFA (n=156) in patients with RA was compared with BARI (n=138). Selection bias was reduced to a minimum using propensity score-based inverse probability of treatment weighting (IPTW). The Clinical Disease Activity Index (CDAI) trajectory for patients who started TOFA or BARI was analysed using growth mixture modelling (GMM). RESULTS: No significant difference was observed in patient characteristics between the TOFA and BARI groups in after adjustment by propensity score-based IPTW. The BARI group had a significantly higher rate of CDAI remission at week 24 after the introduction of JAK inhibitors than the TOFA group. The treatment-resistant group defined by GMM, comprising patients who did not achieve low disease activity at week 24, was more likely to include those who had received many biological disease-modifying antirheumatic drugs (bDMARDs) before the introduction of JAK inhibitors and those who received TOFA. Among patients with RA who received TOFA, those who had received ≥4 bDMARDs before the introduction of TOFA were more likely to be classified into the treatment-resistant group. CONCLUSIONS: BARI showed a similar safety profile and better clinical outcome when compared with TOFA after reduction to a minimum of selection bias. However, these were observed in a small population. Accordingly, further investigation is required in an accurately powered head-to-head trial.
引用
- Miyazaki Y, Nakano K, Nakayamada S, et al. Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting. Ann Rheum Dis. 2021. PMID: 33827788. doi:10.1136/annrheumdis-2020-219699
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。